COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,757 Articles (22,943 medRxiv, 8,814 bioRxiv)

Most recent first Previous |  Page 390: Articles 3891-3900  | Next

Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2
Connor, R. I., Sakharkar, M. I., Rappazzo, C. G., Kaku, C. I., Curtis, N. C., Shin, S., Wieland-Alter, W. F., Weiner, J. A., Ackerman, M. E., Walker, L. M., Lee, J., Wright, P. F.
10.1101/2023.09.19.558444 — Posted: 2023-09-20
Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, Against SARS-CoV-2 Challenge in Nonhuman Primates
Awasthi, M., Macaluso, A., Myscofski, D., Prigge, J., Koide, F., Noyce, R. S., Fogarty, S., Stillwell, H., Goebel, S. J., Daugherty, B., Nasar, F., Bavari, S., Lederman, S.
10.1101/2023.09.19.558485 — Posted: 2023-09-20
High-affinity binding to the SARS-CoV-2 spike trimer by a nanostructured, trivalent protein-DNA synthetic antibody
Xu, Y., Zheng, R., Prasad, A., Liu, M., Wan, Z., Zhou, X., Porter, R. M., Sample, M., Poppleton, E., Procyk, J., Liu, H., Li, Y., Wang, S., Yan, H., Sulc, P., Stephanopoulos, N.
10.1101/2023.09.18.558353 — Posted: 2023-09-19
Sex-specific differences in physiological parameters related to SARS-CoV-2 infections among a national cohort (COVI-GAPP study)
Grossmann, K., Risch, M., Markovic, A., Aeschbacher, S., Weideli, O. C., Velez, L., Kovac, M., Pereira, F., Wohlwend, N., Risch, C., Hillmann, D., Lung, T., Renz, H., Twerenbold, R., Rotenbühler, M., Leibovitz, D., Kovacevic, V., Klaver, P., Brakenhoff, T. B., Franks, B., Mitratza, M., Downward, G. S., Dowling, A., Montes, S., Grobbee, D. E., Cronin, M., Conen, D., Goodale, B. M., Risch, L., COVID-RED consortium
10.1101/2023.09.17.23295693 — Posted: 2023-09-18
Can we start to ignore the SARS-CoV-2 disease?
Nesteruk, I.
10.1101/2023.09.18.23295709 — Posted: 2023-09-18
Adherence Behaviors to Prevent COVID: The Role of Anxiety and Prosocial Behaviors
Corbera, S., Marin-Chollom, A. M.
10.1101/2023.09.18.23295630 — Posted: 2023-09-18
Evidence associating neutrophilia, lung damage, hyperlactatemia, blood acidosis, impaired oxygen transport, and mortality in critically ill COVID-19 patients
Ali, S. S.
10.1101/2023.09.17.558185 — Posted: 2023-09-18
Third dose COVID-19 mRNA vaccine enhances IgG4 isotype switching and recognition of Omicron subvariants by memory B cells after with mRNA but not adenovirus priming
Hartley, G. E., Fryer, H. A., Gill, P. A., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O'Hehir, R. E., Edwards, E. S. J., van Zelm, M. C.
10.1101/2023.09.15.557929 — Posted: 2023-09-18
A highly divergent SARS-CoV-2 lineage B.1.1 sample in a patient with long-term COVID-19
Nabieva, E., Komissarov, A. B., Klink, G. V., Zaitsev, S. V., Sergeeva, M., Fadeev, A. V., Komissarova, K., Ivanova, A., Pisareva, M., Kudrya, K., Danilenko, D., Lioznov, D., Hisner, R., Gueli, F., Peacock, T. P., Roemer, C., Bazykin, G. A.
10.1101/2023.09.14.23295379 — Posted: 2023-09-17
Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA
McGee, J. E., Kirsch, J. R., Kenney, D., Chavez, E., Shih, T.-Y., Douam, F., Wong, W. W., Grinstaff, M. W.
10.1101/2023.09.15.557994 — Posted: 2023-09-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).